Patents by Inventor Kenneth William Batchelor

Kenneth William Batchelor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators
    Publication number: 20100261772
    Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
    Type: Application
    Filed: May 24, 2010
    Publication date: October 14, 2010
    Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
  • Cycloalkylidene compounds as selective estrogen receptor modulators
    Patent number: 7723393
    Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 25, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
  • Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators
    Publication number: 20080167360
    Abstract: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
    Type: Application
    Filed: May 24, 2006
    Publication date: July 10, 2008
    Inventors: Jing Fang, Dennis Heyer, Subba Reddy Katamreddy, Kenneth William Batchelor, Richard Dana Caldwell
  • Androstenones
    Patent number: 5998427
    Abstract: The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: December 7, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye
  • Androstenones
    Patent number: 5977126
    Abstract: The present invention relates to methods for preparing and using compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (A) wherein X, W, Z, R.sup.4, and R.sup.5, are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: November 2, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye
  • Androstenone derivative
    Patent number: 5846976
    Abstract: The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: December 8, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye, George F. Dorsey, Jr., Robert A. Mook, Jr.
  • Androstenones
    Patent number: 5817818
    Abstract: The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (A) or (B) wherein X, W, Z, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: October 6, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Kenneth William Batchelor, Stephen Vernon Frye